AdCom vote provides US FDA with ammo to OK third COVID-19 vaccine

27 February 2021
fda_big

Not surprisingly, given rather positive  briefing documents from US Food and Drug Administration staffers earlier this week, the agency’s Vaccines and Related Biological Products Advisory Committee gave the thumbs up for COVID-19 vaccine Janssen to be approved for emergency use authorization (EUA) following deliberations on Friday.

The non-binding decision, which was adopted by a vote of 22 to 0 by the FDA’s AdCom, comes as the Biden administration works to ramp up the supply of vaccine doses and get Americans vaccinated as quickly as possible, as the US death toll from COVID-19 surpassed 500,000 in the past week.

The vote compares to a 17-4 vote for the first authorized COVID-19 vaccine, from Pfizer (NYSE: PFE) and Germany’s BioNTech (Nasdaq: BNTX), and a 21-0 vote, with one abstention, for Moderna’s (Nasdaq: MRNA) vaccine.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical